53results about How to "High remission rate" patented technology

The invention discloses lactobacillus paracasei Lc19 and a microbial preparation containing the lactobacillus paracasei Lc19. The lactobacillus paracasei Lc19 is preserved in the China General Microbiological Culture Collection Center, and the preservation number of the lactobacillus paracasei Lc19 is CGMCC NO.17827; the lactobacillus paracasei Lc19 not only has a remarkable curative effect on constipation and colitis, but also can improve various characteristic intestinal related florae of constipation and colitis in a targeted manner, improve the abundance of various beneficial bacteria, reduce the abundance of various harmful bacteria, maintain the balance of the intestinal florae, and greatly improve the capability of recovering the health and diversification of the intestinal florae; the lactobacillus paracasei Lc19 also has the advantages of being convenient to eat, simple in treatment, high in remission rate, free of toxic and side effects and the like.

Disclosed are compounds of Formula (I): (I) or stereoisomers, salts, or prodrugs thereof, wherein: (i) R1 and R2 are independently C1-C4 alkyl, or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; and Q is H, C1-6alkyl, phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents, and G is defined herein. Also disclosed are method of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. There compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and chronic inflammatory disease.

Disclosed are compounds of Formula (I)or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, benzyl, —OR4, and / or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Embodiments of the present invention are directed to uses of Interleukin-12 (IL-12) in enhancing or stimulating hematopoiesis to yield hematopoietic recovery in a mammal in need. Particular embodiments of the invention are directed to uses of IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other embodiments include uses of IL-12 to ameliorate various hematopoietic deficiencies. Still other embodiments are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cell, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed embodiments are directed to uses of Il-12 for bone marrow preservation or recovery.

Disclosed are compounds of Formula (I)or pharmaceutically acceptable salts thereof, whereinQ isR1 is alkyl or aryl, said aryl optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, —OR4, and / or halogen;and R2, R3, R4, and n are defined herein.Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formula (I)or pharmaceutically acceptable salts thereof, whereinQ isR1 is cycloalkyl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, —OR4, and / or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as vascular disease and autoimmune diseases.

Disclosed are compounds of Formula (I)or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:A isQ is a substituted 5-membered monocyclic heteroaryl group;W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formula (I):or stereoisomers, N-oxides, salts, or prodrugs thereof; wherein: Ring A is phenyl or 5- to 6-membered heteroaryl; (i) R1 and R2 are independently C1-C4 alkyl; or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; Q is phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents; and R3, L1, L2, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

The invention relates to the technical field of medical detection, in particular to a detection kit for minute residues of B-cell acute lymphocyte leukemia. The detection kit comprises anti CD10, CD19, CD20, CD34, CD38 and CD45 antibodies labeled by different fluoresceins. The detection kit comprises six monoclonal antibody combinations of leukocyte differentiation antigen, and a fluorescence labeling and flow cytometric detection technology is combined to realize that one-time flow cytometric detection can quickly and accurately identify the level and typing of abnormal cells of the minute residues of the B-cell acute lymphocyte leukemia, the obtained detection index can be used as an intermediate result to intuitively judge the prognosis conditions of B-cell acute lymphocyte leukemia patients, and thus important guiding significance is provided for the formulation of clinical treatment schemes for the leukemia patients.

The invention discloses chimeric antigen receptor-T cells secreting and expressing IL15RA-IL15 fusion proteins and CCL21 chemotactic factors as well as application thereof. Super IL15 can promote activation and proliferation of T (especially memory T) cells, NK cells and NKT cells; and CCL21 can recruit peripheral CCR7-positive initial T cells, memory T cells and dendritic cells (DC) into lymphoidtissue or tumor lesions so as to activate active anti-tumor immune response (such as cancer memory T cells) in the body, thereby significantly improving efficiency and remission rate, as well as reducing recurrence rate after remission.

The invention relates to an everolimus pharmaceutical composition. Specifically, the pharmaceutical composition includes an everolimus solid dispersion in a form of a microparticle; a diluent, a lubricant, an optional disintegrant, an optional binder, wherein the everolimus solid dispersion includes: everolimus, antioxidants, carriers, dispersants. The invention also relates to pharmaceutical useof the everolimus solid dispersion, the everolimus solid pharmaceutical composition and the everolimus solid dispersion. The pharmaceutical composition and the solid dispersion exhibit excellent technical effects such as excellent dissolution properties, physical stability, and chemical stability.

The invention provides a reagent composition for screening and / or diagnosing clonal diseases by a one-step method and application of the reagent composition. The reagent composition comprises eight groups of antibodies and is a flow cytometry detection composition capable of being used for one-step screening and / or diagnosis of clonal diseases, a five-tube parallel scheme is used during application, the first group of antibodies and the second group of antibodies are respectively used for different tube samples, the third group of antibodies and the sixth group of antibodies are used for the same tube sample, the fourth group of antibodies and the seventh group of antibodies are used for the same tube sample, and the fifth group of antibodies and the eighth group of antibodies are used for the same tube sample. The reagent composition disclosed by the invention can be applied to flow cytometry one-step screening / diagnosis of various clonal diseases and other abnormalities, comprising acute leukemia, mature lymphocyte tumor, chronic myeloid tumor, night paroxysmal sleep hemoglobinuria, metastatic cancer, precancerous lesions, rare normal human polymorphisms, aplastic anemia, other immune cell subset abnormalities and the like.

The present invention belongs to the field of Chinese medicine technology, and especially a kind of compound Chinese medicine preparation for treating headache and / or dysmenorrhea caused by stagnation of Qi and blood stasis and its preparation process. The compound Chinese medicine preparation is developed based on the Chinese medicine theory of promoting blood circulation and dispersing blood clots to stop pain, and is prepared with corydalis tuber, trogopterus dung, frankincense, myrrh and evodia fruit and through grinding or extracting, adding medicinal supplementary material and further processing to prepare granule, tablet, capsule, etc. Clinical application shows that the compound Chinese medicine preparation has high pain relieving effect and no adverse reaction. The compound Chinese medicine preparation may be also used for treating pain caused by other causes.

The invention discloses a microbial preparation with inactivated streptococcus thermophilus MN002 as well as a preparation method and application of the microbial preparation. The streptococcus thermophilus MN002 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on May 7, 2010, and the preservation number is CGMCC No.3817. The inactivated streptococcus thermophilus MN002 product disclosed by the invention has the effects of improving colitis and characteristic intestinal flora thereof, and improving constipation and characteristic intestinal flora thereof.

The invention relates to a Chinese medicinal preparation for treating acquired immunodeficiency syndrome, which is mainly used for solving the problems of large side effects and poor treatment effect caused by the adoption of a western medicine treatment way for treating acquired immunodeficiency syndrome at present. The Chinese medicinal preparation is characterized by consisting of the following components in parts by weight: 5-20 parts of red-rooted salvia root, 5-20 parts of isatis root, 5-20 parts of honeysuckle flower, 5-25 parts of coptis root, 5-20 parts of lightyellow sophora root, 5-25 parts of gentian, 5-25 parts of sessile stemona root, 5-25 parts of lucid ganoderma, 5-15 parts of calculus bovis factitius, 5-20 parts of artificial bear gall powder, 5-20 parts of Chinese thorowax root, 5-25 parts of selaginella doederleinii hieron, 5-25 parts of black nightshade herb, 5-25 parts of barbed skullcap herb and 5-25 parts of Chinese lobelia herb. The Chinese medicinal preparation for treating acquired immunodeficiency syndrome has the advantages of low cost, good curative effect, high relieving rate and long survival period.

The invention discloses a waist joint zygapophysis cage and an implanting device thereof. The waist joint zygapophysis cage comprises an oblate spheroid, and both ends of the oblate spheroid are provided with an upper cylinder and a lower cylinder respectively which have coincided center shafts and the same diameter; the oblate spheroid is 6 mm in diameter and 4 mm in height; the diameters of the upper cylinder and the lower cylinder are 2 mm, the upper cylinder is 2 mm in height, and the lower cylinder is 1mm in height; and the oblate spheroid, the upper cylinder and the lower cylinder are made of cortical bone materials of adult thighbone. The implanting device comprises a positioning device, a working channel, a straight drill, a spherical drill and an implanting machine. The waist joint zygapophysis cage has the advantages of improving the medium and long term fusion rates of the lumbar facet joint and the remission rate of postoperative symptoms, eliminating the loosening and breaking of bolts and reducing side effects of bolts such as neurologic damage and the like caused by epidural rupture and vertebral canal puncture. The implanting device has the advantages of simple structure, easy operation and good use effect.

The present invention provides a bispecific chimeric antigen receptor combining two single chain antibodies, a coding gene, a combined expression vector, a method for preparing a recombinant lentivirus, a method for preparing CD3+T genetically modified by the bispecific chimeric antigen receptor combining the two single chain antibodies, and use of the genetically-modified CD3+T, and the bispecific chimeric antigen receptor combining the two single chain antibodies includes a CD8 signal peptide, an antigen binding domain composed of the two different single chain antibodies, a transmembrane domain, and an intracellular signaling domain. The treatment of patients with CD19 target loss recurrence and plasma cell tumor can be achieved, and a more effective treatment route is provided for tumor diseases.

The invention provides a traditional Chinese medicine composition for treating leukemia. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicines by weight: 30 g of heterophylly falsestarwort root, 30 g of safflower, 30 g of Chinese angelica, 30 g of membranous milkvetch root, 30 g of radix paeoniae alba, 12 g of radix rehmanniae, 15 g of indigo naturalis, 9 g of herba epimedii, 15 g of radix salviae miltiorrhizae, 30 g of barbed skullcap herb, 30 g of spreading hedyotis herb, 12 g of glossy privet fruit, 18 g of kudzuvine root, 20 g of cortex moutan, 15 g of rhizoma atractylodis macrocephalae, 20 g of rhizoma polygonati, 15 g of indigowoad root, 12 g of cantharides, and 10 g of giant knotweed. The traditional Chinese medicine composition provided by the invention has an obvious curative effect on treating leukemia.

Disclosed are compounds of Formula (I): (I) or stereoisomers, salts, or prodrugs thereof, wherein: (i) R1 and R2 are independently C1-C4 alkyl, or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; and Q is H, C1-6alkyl, phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents, and G is defined herein. Also disclosed are method of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. There compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and chronic inflammatory disease.

The invention provides traditional Chinese medicinal enteric-coated tablets for treating proctitis, colitis and irritable bowel syndrome, as well as a preparation method and application thereof. Active components for preparing the traditional Chinese medicinal enteric-coated tablets comprise the following traditional Chinese medicinal raw materials in parts by weight: 200-800 parts of smoked plum, 50-400 parts of golden thread, 50-400 parts of dried ginger, 50-400 parts of costustoot, 50-300 parts of pericarpium papaveris, and 50-300 parts of rhizoma corydalis. Clinical researches on ulcerative colitis prove that, the traditional Chinese medicinal enteric-coated tablets have a cure rate of 59.1 percent in a treatment group, and a total effective rate of 98.1 percent. Clinical researches on irritable bowel syndrome prove that traditional Chinese medicinal enteric-coated tablets have a complete remission rate of 67.8 percent in the treatment group, and a total effective rate of 95.2 percent. In clinical researches on proctitis, the traditional Chinese medicinal enteric-coated tablets are used for treating 36 cases, wherein 32 cases are cured, 3 cases are improved, 1 case is invalid, and the total effective rate is 88.8 percent. The researches prove that the enteric-coated tablets have remarkable advantages and improvement in treatment after the preparation and dose forms are improved, and are advantageous to clinical application. The traditional Chinese medicinal enteric-coated tablets are easily available in raw materials, simple in method and pollution free, is suitable for industrial production, and has higher application value.

The invention features new a method for treating inflammatory bowel disease, including Crohn's Disease (CD) or ulcerative colitis in a human patient, comprising administering to a patient a combination therapy comprising an anti-α4β7 antibody, a TNFα antagonist, and an immunomodulator.

The invention relates to a traditional Chinese medicine for treating senile xerophthalmia. The traditional Chinese medicine is characterized by comprising raw materials in parts by weight: 6-9g of divaricate saposhnikovia root, 6-9g of lightyellow sophora root, 4-6g of belvedere fruit, 6-9g of white peony root, 6-9g of Chinese angelica, 6-9g of cassia seeds, 6-9g of cape jasmine, 4-6g of dendrobium, 4-6g of dwarf lilyturf tuber, 4-6g of fragrant Solomonseal rhizome, 6-9g of honeysuckle stem, 6-9g of lotus seeds, 6-9g of platycladi seeds, 6-9g of dried rehmannia root, 6-9g of poria pararadicis, 3-4g of fructus schizandrae, 6-8g of lycium berry, 6-9g of ligusticum root, 4-6g of typha pollen, 6-9g of salvia root, 6-9g of suberect spatholobus stem and 4-6g of jujube. Treating the senile xerophthalmia by using the traditional Chinese medicine regards dispelling wind with arresting itching, nourishing liver and heart, nourishing Yin with improving eyesight and promoting blood circulation to remove meridian obstruction as rules of the treatment, and the treatment is usually dialectically carried out according to different disease types clinically.

The invention relates to a combined medicine for curing treatment-resistant depression (TRD), which is characterized in that the combined medicine comprises paroxetine and sodium valproate. The invention also provides applications of the combined medicine. The invention has the advantages that the research on the TRD synergia strategy is provided for the first time in China, the combined medicine of paroxetine and sodium valproate, and the applications of the combined medicine in the preparation of medicine for curing the TRD are provided for the first time, the paroxetine combined with the sodium valproate for curing the TRD has higher remission rate, and the tolerance is high, so that the combined medicine can be taken as the new intensive treatment scheme for curing the TRD.

Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other methods include administering IL-12 to ameliorate various hematopoietic deficiencies. Still other methods are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed methods are directed to uses of IL-12 for bone marrow preservation or recovery.

The invention discloses a traditional Chinese medicine preparation for treating prosopospasm. The preparation is prepared from the following medicinal materials in parts by weight: 15-25 parts of ligusticum wallichii, 5-12 parts of anaphalis lactea, 3-7 parts of pulvis fellis suis, 1-4 parts of trichosanthes kirilowii maxim, 5-12 parts of rabbit hearts, 3-9 parts of cornu cervi degelatinatum, 3-12 parts of polyporus umbellatus, 12-25 parts of radix phytolaccae, 5-13 parts of daphne giraldii nitsche, 3-9 parts of semen sophorae, 5-15 parts of ellpticleaf spurgentian root, 10-20 parts of rhizoma dioscoreae septemlobae, 12-24 parts of radices stellariae dichotomae and 5-10 parts of herba siegesbeckiae. The traditional Chinese medicine preparation is convenient to use, has good absorption effect and no adverse, toxic or side effect, and is simple in preparation.

The invention discloses a combined chimerism antigen receptor, an expression vector, lentivirus and a T-cell. The combined chimerism antigen receptor comprises chimeric protein CAR19 and chimeric protein CAR22, and the chimeric protein CAR19 is formed by coupling a fragment comprising at least a single chain antibody that specifically identifies CD19 and a T-cell activation motif; the CAR22 is formed by coupling a fragment comprising at least a single chain antibody that specifically identifies CD22 and a T-cell activation motif. In addition, the expression vector, lentivirus and T-cell are based on the principle of CART, combined with CAR19T and CAR22T to effectively reduce high recurrence of CAR19T and to prevent severe CR of the CAR19T. The combined chimerism antigen receptor, an expression vector, lentivirus and a T-cell provide more effective treatment for tumor diseases.

The invention discloses traditional Chinese medicine for treating prosopoplegia. The traditional Chinese medicine is prepared by, by weight, 5-12 parts of mountainous cochlearia, 6-10 parts of sticktight, 3-10 parts of Tongguanteng, 10-17 parts of thlaspi, 7-16 parts of giant typhonium rhizome, 4-9 parts of endive, 2-9 parts of Chinese parsnip root, 15-28 parts of yellow yam, 10-19 parts of climbing fern, 3-12 parts of Chinese starjasmine stem, 6-13 parts of sargentgloryvine stem, 9-21 parts of holly bark and 12-20 parts of pubescent angelica root. The traditional Chinese medicine is a pure traditional Chinese medicine preparation, is nontoxic to human body, especially liver, can calm liver and ease pain, activate and nourish blood, astring yin and stop sweating, calm heart, soothe nerve and resolve depression, calm endogenous wind and stop spasm, dispel wind, cold and dampness, dredging collaterals, strengthen tendons and removing stasis, has remarkable effect on comprehensively treating prosopoplegia and can achieve the objectives of easing pain, tonifying lung, tranquilizing, clearing heat and improving immunity. The traditional Chinese medicine is simple to prepare and nontoxic.

The present invention discloses a biochip for assisting large intestine cancer targeted therapy. Meanwhile, the present invention further discloses a use method of the biochip and a preparation method for a bio-chip detection sample. According to the present invention, multiple gene loci can be simultaneously detected, such that the biochip of the present invention has characteristics of excellent performance and exact treatment effect prediction compared with the traditional single-detection K-RAS mutation chip, the large intestine cancer treatment remission rate of Erbitux can be increased to 41% from 36%, and the disease control rate can be increased to 82% from 76%; and due to use of immune microarray detection, advantages of short time consuming, high sensitivity, high accuracy, high throughput, and low cost of individual detection are provided.

Disclosed are compounds of Formula (I)or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:A isQ is a substituted 5-membered monocyclic heteroaryl group;W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.